Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TQ-B211 vs Herceptin plus docetaxel in HER2-positive metastatic breast cancer
CTR20181909Phase 3Completed
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Oct 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of trastuzumab-qyyp in breast cancer, sponsored by Chia Tai-Tianqing Pharmaceutical Group. Started Oct 2018; status: completed.
02
Drugs
trastuzumab-qyyp
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20181909.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20181909.